NKTR — Nektar Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.32bn
- $692.66m
- $55.23m
Nektar Therapeutics' experimental eczema drug meets main goal of mid-stage trial (updated)
Brief: Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis
Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial
Brief: Nektar Therapeutics Increases Authorized Shares To 390 Million
Nektar Therapeutics reports results for the quarter ended March 31 - Earnings Summary
Nektar Therapeutics expected to post a loss of 16 cents a share - Earnings Preview
Brief: Nektar Therapeutics - Enters Equity Distribution Agreement Up To $75 Million - SEC Filing
Brief: Nektar Therapeutics Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing
Nektar Therapeutics reports results for the quarter ended December 31 - Earnings Summary
Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview
Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview
Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview
Brief: Nektar Announces Clinical Trial Agreement To Evaluate Rezpegaldesleukin
Brief: Nektar Therapeutics Announces Completion Of Target Enrollment In Rezolve-Ad Phase 2B Clinical Trial Of Rezpegaldesleukin In Patients With Moderate-To-Severe Atopic Dermatitis
U.S. RESEARCH ROUNDUP-GE Healthcare, Summit Materials, Tapestry
Nektar Therapeutics reports results for the quarter ended in September 30 - Earnings Summary
U.S. RESEARCH ROUNDUP-Amazon, Chevron, Mastercard
Nektar Therapeutics expected to post a loss of 21 cents a share - Earnings Preview
Nektar Therapeutics reports results for the quarter ended in June - Earnings Summary